News & Updates

The oral JAK1 inhibitor povorcitinib elicits clinical response in the subpopulation of hidradenitis suppurativa (HS) patients who had prior treatment with anti-TNF, according to pooled 24-week data from the phase III STOP-HS trials.

In the treatment of patients with acute, intermediate-risk pulmonary embolism (PE), administering ultrasound-facilitated, catheter-directed thrombolysis (USCDT) on top of anticoagulation results in better short-term outcomes compared with anticoagulation alone, as shown in the multinational, adaptive-design, open-label HI-PEITHO trial.

Once-daily application of roflumilast cream 0.3% is associated with a significantly higher rate of treatment success on the Investigator's Global Assessment (IGA) scale in Chinese patients with plaque psoriasis compared with a vehicle cream, according to the phase III DERMIS-1 and -2 studies presented at AAD 2026.

Patients with psoriasis appear to have the lowest risk of developing psoriatic arthritis (PsA) when they are treated with IL-23 inhibitors than with other immunomodulatory agents, according to a real-world study.

Administrating pegfilgrastim 72 h after chemotherapy, compared with 24- and 48-h administration, results in reduced pegfilgrastim-induced bone pain (PIBP) and does not appear to increase the rates of neutropenia or febrile neutropenia (FN), reports a study.

The first-in-class KRAS G12D–targeted protein degrader setidegrasib has demonstrated antitumour activity in patients with previously treated advanced non–small-cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma harbouring the KRAS G12D mutation, according to a phase I study.